The FDA will discuss the safety and product quality of CBD-derived compounds in a public hearing Friday.
Pot stocks were trading lower Friday ahead of a key Food and Drug Administration hearing on the efficacy of food products infused with cannabidiol, the non-THC active ingredient in cannabis.
The public hearing is intended to obtain scientific data and information about the cannabis-derived product.
Download Now: To be a profitable investor you first need to know the rules. Get Jim Cramer’s 25 Rules for Investing Special Report
The FDA will webcast the public hearing here. The event will feature opening remarks from Ned Sharpless, the acting FDA commissioner, oral comments and formal presentations from professors.
Shares of Tilray (TLRY) were down 2.28% to $38.23 in trading Friday.